Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q4 FY24 results · Jan–Mar 2024
Marksans Pharma reported revenue from operations of ₹560.01 crore (up 15.2% from Q4 FY23) and net profit of ₹77.64 crore (down 6.1% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 560.01 | 485.98 | +15.2% | 586.13 | −4.5% |
| Other income | 16.53 | 11.01 | +50.1% | 4.80 | +244.4% |
| Total income | 576.54 | 496.99 | +16.0% | 590.93 | −2.4% |
| Profit before tax | 100.28 | 104.17 | −3.7% | 112.66 | −11.0% |
| Net profit for the period | 77.64 | 82.71 | −6.1% | 82.97 | −6.4% |
| Attributable to shareholders of the company | 72.66 | — | — | 83.23 | −12.7% |
| EPS, basic (₹) | 1.73 | 1.97 | −12.2% | 1.84 | −6.0% |
| Net margin (%) | 13.9 | 17.0 | 14.2 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 225.20 | 153.04 | +47.1% | 241.36 | −6.7% |
| Other income | 12.19 | 4.30 | +183.4% | 1.32 | +820.3% |
| Total income | 237.39 | 157.35 | +50.9% | 242.69 | −2.2% |
| Profit before tax | 38.40 | 22.84 | +68.1% | 34.60 | +11.0% |
| Net profit for the period | 32.99 | 17.81 | +85.3% | 25.29 | +30.5% |
| EPS, basic (₹) | 0.73 | 0.43 | +69.8% | 0.56 | +30.4% |
| Net margin (%) | 14.7 | 11.6 | 10.5 |
Consolidated
- Filed with BSE
- 01 Jun 2024, 14:47 IST
- Board meeting
- 30 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Jun 2024, 14:47 IST
- Board meeting
- 30 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE